{"id":1640,"date":"2023-06-25T17:29:04","date_gmt":"2023-06-25T17:29:04","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/anagrelide\/"},"modified":"2023-06-25T17:29:04","modified_gmt":"2023-06-25T17:29:04","slug":"anagrelide","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/anagrelide\/","title":{"rendered":"Anagrelide"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/kidneydiseaseclinic.net\/renaldrugs\/img\/Anagrelide.JPG\" ><\/p>\n<h1>Anagrelide<\/h1>\n<p><H3>  CLINICAL USE <\/H3><br \/>\nPlatelet-reducing agent<br \/>\n<H3> DOSE IN NORMAL RENAL FUNCTION  <\/H3><br \/>\n1\u201310 mg daily in divided doses; maximum<br \/>\nsingle dose 2.5 mg; normal range 1\u20133 mg<br \/>\ndaily<br \/>\n<H3>  PHARMACOKINETICS    <\/H3><br \/>\n<LI> Molecular weight &#038;nbsp  &#038;nbsp &#038;nbsp &#038;nbsp &#038;nbsp &#038;nbsp &#038;nbsp &#038;nbsp  &#038;nbsp &#038;nbsp &#038;nbsp &#038;nbsp &#038;nbsp :<br \/>\n292.5 (as<br \/>\nhydrochloride)\n<\/li>\n<li>  %Protein binding  &#038;nbsp &#038;nbsp &#038;nbsp  &#038;nbsp  &#038;nbsp  &#038;nbsp &#038;nbsp &#038;nbsp &#038;nbsp &#038;nbsp &#038;nbsp &#038;nbsp &#038;nbsp :<br \/>\nNo data\n<\/li>\n<li>  %Excreted unchanged in urine &#038;nbsp &#038;nbsp :<br \/>\n<1\n<\/li>\n<p><LI> Volume of distribution (L\/kg) &#038;nbsp &#038;nbsp &#038;nbsp :<br \/>\n12\n<\/li>\n<p><LI>half-life \u2013 normal\/ESRD (hrs)&#038;nbsp &#038;nbsp &#038;nbsp :<br \/>\n1.3<br \/>\n<H3>  DOSE IN RENAL IMPAIRMENT <\/H3><br \/>\n<H4>GFR (mL\/MIN)<\/H4><br \/>\n30\u201350 Dose as in normal renal function<br \/>\n10\u201330 Dose as in normal renal function,<br \/>\nbut use with caution and keep to<br \/>\nlowest dose possible<br \/>\n<LI> <10 &#038;nbsp &#038;nbsp &#038;nbsp &#038;nbsp &#038;nbsp : \nDose as in normal renal function, \nbut use with caution and keep to \nlowest dose possible\n<H3> DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES  <\/H3><br \/>\n<LI> CAPD  &#038;nbsp &#038;nbsp &#038;nbsp  &#038;nbsp &#038;nbsp &#038;nbsp &#038;nbsp &#038;nbsp:<br \/>\nUnknown dialysability. Dose as in<br \/>\nGFR <10 mL\/min\n\n\n<li> HD &#038;nbsp  &#038;nbsp &#038;nbsp  &#038;nbsp &#038;nbsp  &#038;nbsp &#038;nbsp &#038;nbsp &#038;nbsp &#038;nbsp :<br \/>\nUnknown dialysability. Dose as in<br \/>\nGFR <10 mL\/min\n<LI>HDF\/high flux  &#038;nbsp :<br \/>\nUnknown dialysability. Dose as in<br \/>\nGFR <10 mL\/min\n<LI>CAV\/VVHD  &#038;nbsp &#038;nbsp &#038;nbsp:<br \/>\nUnknown dialysability. Dose as in<br \/>\nGFR=10\u201330 mL\/min<br \/>\n<H3> IMPORTANT DRUG INTERACTIONS  <\/H3><br \/>\nPotentially hazardous interactions with other drugs<\/p>\n<li>Cilostazol: avoid concomitant use\n<p>Phosphodiesterase inhibitors: avoid <\/p>\n<p>concomitant use with milrinone and<br \/>\nenoximone<\/p>\n<li>spirin: potential risks and benefits must\n<p>first be assessed, additive antiplatelet effect<\/p>\n<li>Grapefruit juice: may reduce clearance of\n<p>anagrelide<br \/>\n<H3> ADMINISTRATION  <\/H3><br \/>\n<H4> Reconstition<\/H4><br \/>\n\u2013<br \/>\n<H4>  Route  <\/H4><br \/>\nOral<\/p>\n<p><H4>  Rate of Administration  <\/H4><br \/>\n\u2013<br \/>\n<H4>Comments<\/H4><br \/>\n\u2013<br \/>\n<H4>  OTHER INFORMATION  <\/H4><\/p>\n<li>May cause fluid retention, tachycardia and\n<p>various cardiac complications<\/p>\n<li>Rarely can increase creatinine levels\n<li>High doses can cause a drop in blood\n<p>pressure<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Anagrelide CLINICAL USE Platelet-reducing agent DOSE IN NORMAL RENAL FUNCTION<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-1640","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1640","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=1640"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1640\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=1640"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=1640"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=1640"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}